Background. This retrospective study aimed to characterize the long-term (>24 months) safety profile of zoledronic acid (ZA). We\naimed to investigate whether long-term ZA treatment had greater benefits than short-term treatment in patients from southern\nChina with advanced breast cancer (ABC) with bone metastasis. Patients and Methods. A total of 566 metastatic breast cancer\ncases were included and divided into two groups according to the duration of ZA treatment. The included patients had at least one\nlytic bone lesion and had no skeletal-related events (SREs) prior to ZA therapy.Theprimary endpoint was to analyze the safety and\nlong-term adverse effects, which covered osteonecrosis of jaws (ONJ), renal impairment, and hearing impairment. The second\nobjective was to determine the efficacy of long-term ZA treatment by the incidence of SREs. Results. Fifteen patients were\ndiagnosed with.....................
Loading....